Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MILOPHENE vs CLOMID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.
Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (Gn RH) and subsequent LH and FSH release, stimulating ovulation.
Treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors,Reduction in incidence of invasive breast cancer in women at high risk (FDA-approved),Off-label: ovulation induction in anovulatory infertility
Treatment of ovulatory dysfunction in women desiring pregnancy (FDA approved),Off-label: treatment of male infertility (oligospermia)
1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.
50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.
Terminal elimination half-life is 18-24 hours, supporting once-daily dosing; prolonged in renal impairment.
Terminal half-life is 5–7 days for zuclomiphene (active isomer), with prolonged elimination due to enterohepatic recirculation.
Metabolized primarily by CYP3A4 and CYP2D6 to active metabolites (e.g., N-desmethylmilophene, 4-hydroxymilophene). Undergoes enterohepatic recirculation.
Hepatic via CYP3A4 and CYP2D6; undergoes enterohepatic circulation; terminal half-life ~5-7 days
Primarily renal excretion of unchanged drug (70-80%), with 10-15% as glucuronide conjugate; biliary/fecal elimination accounts for <10%.
Primarily hepatic metabolism; metabolites excreted in feces (42%) and urine (8% unchanged).
92-96% bound to albumin.
Highly protein bound (>99%), primarily to albumin.
0.3-0.4 L/kg, indicating distribution primarily in extracellular fluid.
Not well-characterized; limited data suggest a large Vd (>100 L) due to extensive tissue distribution.
Oral: 65-75% with significant first-pass metabolism.
Oral bioavailability is approximately 50% due to first-pass metabolism.
GFR 30-50 m L/min: 75% of normal dose every 6 hours; GFR 15-29 m L/min: 50% of normal dose every 8 hours; GFR <15 m L/min: 25% of normal dose every 12 hours.
No specific adjustment required; use caution in severe impairment (Cr Cl <30 m L/min) as data limited.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 50% of normal dose every 6 hours; Child-Pugh Class C: contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, no adjustment recommended, but monitor liver function.
Children 1 month to 12 years: 0.5-1 mg/kg intravenously every 4-6 hours, maximum 50 mg per dose; infants <1 month: 0.25-0.5 mg/kg every 6-8 hours.
Not indicated for use in children; safety and efficacy not established.
Start at 50% of adult dose, increase based on tolerance and renal function; monitor for neurotoxicity and QT prolongation.
Not indicated for postmenopausal women. Use not recommended in elderly due to lack of efficacy in anovulation.
Boxed Warning: Increased risk of thromboembolic events (deep vein thrombosis, pulmonary embolism) and stroke. Use with caution in patients with history of thromboembolic disorders.
None
Warnings: Thromboembolic events, stroke, endometrial hyperplasia/carcinoma, ovarian cysts, visual disturbances (e.g., cataracts, retinopathy), hepatic impairment, hypercalcemia in bone metastases. Monitor lipid profiles and liver function.
Ovarian hyperstimulation syndrome (OHSS),Ovarian enlargement,Visual disturbances (especially with prolonged use),Multiple pregnancy (increased risk),Ectopic pregnancy,Ovarian cancer risk (theoretical, based on prolonged use)
Contraindications: Hypersensitivity to milophene or any component; pregnancy (Category X); history of thromboembolic disease (e.g., DVT, PE); undiagnosed abnormal genital bleeding; hepatic impairment (severe); concurrent use of anticoagulants.
Pregnancy (Category X),Liver disease or dysfunction,Undiagnosed abnormal vaginal bleeding,Ovarian cyst or enlargement not due to polycystic ovary syndrome,Hypersensitivity to clomiphene or components
Grapefruit juice may increase clomiphene levels; avoid concurrent consumption. No specific food restrictions, but maintain a balanced diet. Limit caffeine intake as it may affect fertility.
No specific food interactions. Avoid grapefruit as it may alter metabolism (theoretical due to CYP3A4 involvement).
MILOPHENE is a dopamine agonist used for hyperprolactinemia. In the first trimester, there is limited human data but no evidence of increased major malformations. Risk cannot be completely excluded. In the second and third trimesters, continued use may be justified if needed. Limited studies suggest no significant increase in adverse fetal outcomes. However, dopamine agonists have been associated with fetal harm in animal studies, so cautious use is warranted throughout pregnancy.
Clomiphene citrate is contraindicated in pregnancy. It is associated with an increased risk of fetal malformations, including neural tube defects, specifically when exposure occurs during the first trimester. Second and third trimester risks are not well studied due to contraindication, but theoretical risks include ovarian hyperstimulation syndrome (OHSS) effects on pregnancy.
MILOPHENE is excreted into human breast milk. The M/P ratio is unknown but assumed to be low based on molecular weight and protein binding. Due to potential adverse effects on the infant (e.g., dopamine receptor blockade), breastfeeding is not recommended during therapy. Alternative treatments or cessation of breastfeeding should be considered.
Safety in breastfeeding is not established. Clomiphene may reduce milk production. The M/P ratio is unknown. It is generally not recommended during breastfeeding.
Pharmacokinetic changes during pregnancy (e.g., increased plasma volume, renal clearance) may require dose adjustment. However, data are limited. Clinical monitoring of prolactin levels and symptom control is recommended. Dose may need to be increased to maintain efficacy, but the lowest effective dose should be used. No specific dose adjustment guidelines exist; therefore, individualized titration based on response is prudent.
No dose adjustments are relevant as clomiphene is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are not applicable due to contraindication.
Milophene (clomiphene citrate) is a selective estrogen receptor modulator used for ovulation induction. Monitor for ovarian hyperstimulation syndrome (OHSS) with pelvic ultrasound. Limit course duration to 6 cycles due to increased risk of ovarian cancer. Use with caution in patients with liver disease or abnormal uterine bleeding. Administer on days 3-7 of menstrual cycle for optimal response.
Monitor ovarian size via ultrasound to reduce risk of ovarian hyperstimulation syndrome (OHSS). Limit course to 3-6 cycles due to increased risk of ovarian tumors. Check pregnancy test before each cycle. Use with caution in liver disease.
Take exactly as prescribed, typically one tablet daily for 5 days starting on cycle day 3, 4, or 5.,Notify your doctor immediately if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Avoid pregnancy before starting treatment; use barrier contraception until instructed.,Multiple births (especially twins) occur in about 10% of pregnancies; discuss this risk.,Report any visual disturbances (blurring, spots, flashes) promptly; discontinue use if they occur.,Do not exceed 6 treatment cycles; prolonged use increases ovarian cancer risk.
Take exactly as prescribed, typically 50 mg daily for 5 days starting on day 5 of menstrual cycle.,Report abdominal pain, bloating, nausea, or weight gain (possible OHSS).,Avoid alcohol due to hepatotoxicity risk.,Most pregnancies occur within first 3 cycles; consider alternative after 6 cycles.,May cause visual disturbances; report blurred vision or spots.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MILOPHENE vs CLOMID, answered by our medical review team.
MILOPHENE is a Selective Estrogen Receptor Modulator that works by MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.. CLOMID is a Selective Estrogen Receptor Modulator that works by Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (Gn RH) and subsequent LH and FSH release, stimulating ovulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MILOPHENE and CLOMID depend on the specific clinical indication. These are both Selective Estrogen Receptor Modulator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MILOPHENE is: 1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.. The standard adult dose of CLOMID is: 50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MILOPHENE and CLOMID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MILOPHENE is classified as Category C. MILOPHENE is a dopamine agonist used for hyperprolactinemia. In the first trimester, there is limited human data but no evidence of increased major malformations. Risk cannot be co. CLOMID is classified as Category C. Clomiphene citrate is contraindicated in pregnancy. It is associated with an increased risk of fetal malformations, including neural tube defects, specifically when exposure occurs. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.